Literature DB >> 28784837

Use of Proteomics To Investigate Kidney Function Decline over 5 Years.

Axel C Carlsson1,2, Erik Ingelsson2,3,4, Johan Sundström2,5, Juan Jesus Carrero6, Stefan Gustafsson2, Tobias Feldreich2,7, Markus Stenemo2, Anders Larsson2, Lars Lind2, Johan Ärnlöv8,7.   

Abstract

BACKGROUND AND OBJECTIVES: Using a discovery/replication approach, we investigated associations between a multiplex panel of 80 circulating proteins associated with cardiovascular pathology or inflammation, and eGFR decline per year and CKD incidence. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used two cohorts, the Prospective Investigation of the Vasculature in Uppsala Seniors Study (PIVUS; n=687, mean age of 70 years, 51% women) and the Uppsala Longitudinal Study of Adult Men (ULSAM; n=360 men, mean age of 78 years), with 5-year follow-up data on eGFR. There were 231 and 206 incident cases of CKD during follow-up in the PIVUS and ULSAM studies, respectively. Proteomic profiling of 80 proteins was assessed by a multiplex assay (proximity extension assay). The assay uses two antibodies for each protein and a PCR step to achieve a high-specific binding and the possibility to measure multiple proteins in parallel, but gives no absolute concentrations.
RESULTS: In the discovery cohort from the PIVUS Study, 28 plasma proteins were significantly associated with eGFR decline per year, taking into account the multiple testing. Twenty of these proteins were significantly associated with eGFR decline per year in the replication cohort from the ULSAM Study after adjustment for age, sex, cardiovascular risk factors, medications, and urinary albumin-to-creatinine ratio (in order of significance: TNF-related apoptosis-inducing ligand receptor 2*, CD40L receptor, TNF receptor 1*, placenta growth factor*, thrombomodulin*, urokinase plasminogen activator surface receptor*, growth/differentiation factor 15*, macrophage colony-stimulating factor 1, fatty acid-binding protein*, cathepsin D, resistin, kallikrein 11*, C-C motif chemokine 3, proteinase-activated receptor 1*, cathepsin L, chitinase 3-like protein 1, TNF receptor 2*, fibroblast growth factor 23*, monocyte chemotactic protein 1, and kallikrein 6). Moreover, 11 of the proteins predicted CKD incidence (marked with * above). No protein consistently predicted eGFR decline per year independently of baseline eGFR in both cohorts.
CONCLUSIONS: Several circulating proteins involved in phosphate homeostasis, inflammation, apoptosis, extracellular matrix remodeling, angiogenesis, and endothelial dysfunction were associated with worsening kidney function. Multiplex proteomics appears to be a promising way of discovering novel aspects of kidney disease pathology.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  Adult; Aged; Albumins; Cardiovascular Diseases; Fatty Acid-Binding Proteins; Fibroblast Growth Factors; Follow-Up Studies; Homeostasis; Longitudinal Studies; Phosphates; Plasminogen; Prospective Studies; Proteomics; Urokinase-Type Plasminogen Activator; apoptosis; creatinine; extracellular matrix; glomerular filtration rate; risk factors

Mesh:

Substances:

Year:  2017        PMID: 28784837      PMCID: PMC5544512          DOI: 10.2215/CJN.08780816

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  43 in total

1.  Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.

Authors:  Monika A Niewczas; Tomohito Gohda; Jan Skupien; Adam M Smiles; William H Walker; Florencia Rosetti; Xavier Cullere; John H Eckfeldt; Alessandro Doria; Tanya N Mayadas; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2012-01-19       Impact factor: 10.121

2.  Renal dysfunction increases the risk of ischemic and hemorrhagic stroke in the general population.

Authors:  Martin J Holzmann; Are Aastveit; Niklas Hammar; Ingmar Jungner; Göran Walldius; Ingar Holme
Journal:  Ann Med       Date:  2011-05-25       Impact factor: 4.709

3.  Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis.

Authors:  Lars Lind; Johan Ärnlöv; Bertil Lindahl; Agneta Siegbahn; Johan Sundström; Erik Ingelsson
Journal:  Atherosclerosis       Date:  2015-07-14       Impact factor: 5.162

4.  The death ligand TRAIL in diabetic nephropathy.

Authors:  Corina Lorz; Alberto Benito-Martín; Anissa Boucherot; Alvaro C Ucero; Maria Pia Rastaldi; Anna Henger; Silvia Armelloni; Beatriz Santamaría; Celine C Berthier; Matthias Kretzler; Jesus Egido; Alberto Ortiz
Journal:  J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 10.121

5.  Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.

Authors:  Maria Lajer; Anders Jorsal; Lise Tarnow; Hans-Henrik Parving; Peter Rossing
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 17.152

Review 6.  New and old markers of progression of diabetic nephropathy.

Authors:  G Jerums; E Premaratne; S Panagiotopoulos; S Clarke; D A Power; R J MacIsaac
Journal:  Diabetes Res Clin Pract       Date:  2008-10-19       Impact factor: 5.602

7.  Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.

Authors:  Ivana Pavik; Philippe Jaeger; Lena Ebner; Carsten A Wagner; Katja Petzold; Daniela Spichtig; Diane Poster; Rudolf P Wüthrich; Stefan Russmann; Andreas L Serra
Journal:  Nephrol Dial Transplant       Date:  2012-11-04       Impact factor: 5.992

8.  Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population.

Authors:  Johanna Helmersson; Bengt Vessby; Anders Larsson; Samar Basu
Journal:  Circulation       Date:  2004-03-22       Impact factor: 29.690

9.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

10.  Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate.

Authors:  Kunihiro Matsushita; Bakhtawar K Mahmoodi; Mark Woodward; Jonathan R Emberson; Tazeen H Jafar; Sun Ha Jee; Kevan R Polkinghorne; Anoop Shankar; David H Smith; Marcello Tonelli; David G Warnock; Chi-Pang Wen; Josef Coresh; Ron T Gansevoort; Brenda R Hemmelgarn; Andrew S Levey
Journal:  JAMA       Date:  2012-05-09       Impact factor: 56.272

View more
  22 in total

1.  The Possibilities to Improve Kidney Health with Proteomics.

Authors:  Stein Ivar Hallan
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-21       Impact factor: 8.237

2.  Longitudinal course of GDF15 levels before acute hospitalization and death in the general population.

Authors:  Juliette Tavenier; Ove Andersen; Jan O Nehlin; Janne Petersen
Journal:  Geroscience       Date:  2021-03-24       Impact factor: 7.713

3.  Circulating Plasma Biomarkers in Biopsy-Confirmed Kidney Disease.

Authors:  Insa M Schmidt; Suraj Sarvode Mothi; Parker C Wilson; Ragnar Palsson; Anand Srivastava; Ingrid F Onul; Zoe A Kibbelaar; Min Zhuo; Afolarin Amodu; Isaac E Stillman; Helmut G Rennke; Benjamin D Humphreys; Sushrut S Waikar
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-10       Impact factor: 8.237

Review 4.  GDF15: A Hormone Conveying Somatic Distress to the Brain.

Authors:  Samuel M Lockhart; Vladimir Saudek; Stephen O'Rahilly
Journal:  Endocr Rev       Date:  2020-08-01       Impact factor: 19.871

5.  Urinary Growth Differentiation Factor-15 (GDF15) levels as a biomarker of adverse outcomes and biopsy findings in chronic kidney disease.

Authors:  Maria Dolores Sanchez-Niño; Alberto Ortiz; Maria Vanessa Perez-Gomez; Soledad Pizarro-Sanchez; Carolina Gracia-Iguacel; Santiago Cano; Pablo Cannata-Ortiz; Jinny Sanchez-Rodriguez; Ana Belen Sanz
Journal:  J Nephrol       Date:  2021-04-13       Impact factor: 3.902

6.  Proteomic profiles before and during weight loss: Results from randomized trial of dietary intervention.

Authors:  Sylwia M Figarska; Joseph Rigdon; Andrea Ganna; Sölve Elmståhl; Lars Lind; Christopher D Gardner; Erik Ingelsson
Journal:  Sci Rep       Date:  2020-05-13       Impact factor: 4.379

Review 7.  TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?

Authors:  Stella Bernardi; Rebecca Voltan; Erika Rimondi; Elisabetta Melloni; Daniela Milani; Carlo Cervellati; Donato Gemmati; Claudio Celeghini; Paola Secchiero; Giorgio Zauli; Veronica Tisato
Journal:  Clin Sci (Lond)       Date:  2019-05-16       Impact factor: 6.124

8.  Plasma Proteomics of Renal Function: A Trans-ethnic Meta-analysis and Mendelian Randomization Study.

Authors:  Pamela Matías-García; Rory Wilson; Qi Guo; Shaza Zaghlool; James Eales; Xiaoguang Xu; Fadi Charchar; John Dormer; Haifa Maalmi; Pascal Schlosser; Mohamed Elhadad; Jana Nano; Sapna Sharma; Annette Peters; Alessia Fornoni; Dennis Mook-Kanamori; Juliane Winkelmann; John Danesh; Emanuele Di Angelantonio; Willem Ouwehand; Nicholas Watkins; David Roberts; Agnese Petrera; Johannes Graumann; Wolfgang Koenig; Kristian Hveem; Christian Jonasson; Anna Köttgen; Adam Butterworth; Marco Prunotto; Stefanie Hauck; Christian Herder; Karsten Suhre; Christian Gieger; Maciej Tomaszewski; Alexander Teumer; Melanie Waldenberger
Journal:  J Am Soc Nephrol       Date:  2021-06-16       Impact factor: 14.978

9.  Dendritic cell maturation in the corneal epithelium with onset of type 2 diabetes is associated with tumor necrosis factor receptor superfamily member 9.

Authors:  Neil S Lagali; Reza A Badian; Xu Liu; Tobias R Feldreich; Johan Ärnlöv; Tor Paaske Utheim; Lars B Dahlin; Olov Rolandsson
Journal:  Sci Rep       Date:  2018-09-24       Impact factor: 4.379

10.  Tumour necrosis factor-related apoptosis-inducing ligand expression in patients with diabetic nephropathy.

Authors:  Wei-Wei Chang; Wei Liang; Xin-Ming Yao; Liu Zhang; Li-Jun Zhu; Chen Yan; Yue-Long Jin; Ying-Shui Yao
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jul-Sep       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.